Navigation Links
MacuLogix Raises $3.6 Million in Series A Round
Date:3/11/2013

HUMMELSTOWN, Pa., March 11, 2013 /PRNewswire/ -- MacuLogix, Inc., a pioneer in the early detection and tracking of age-related macular degeneration (AMD), today announced it has raised $3.6 million in Series A funding. Investors include Berwind Private Equity, Roche Venture Fund, Life Sciences Greenhouse of Central Pennsylvania, and Ben Franklin Technology Partners of Central and Northern Pennsylvania.

The funds will be used to accelerate manufacturing and commercial sales of the MacuLogix' AdaptDx™. The AdaptDx™ is being developed to be the first practical diagnostic for early detection and tracking of AMD. Based on significant advances in the measurement of dark adaptation, the AdaptDx™ will provide doctors with an easy-to-use, functional diagnostic similar to routine perimetry testing for glaucoma. With this important new tool, doctors will be able to intervene at the earliest possible time to prevent vision loss and improve quality of life.

"MacuLogix represents a favorable investment opportunity as it addresses a large and growing market for AMD which is the leading cause of adult vision loss and blindness in developed countries," said A. Laurence Norton , Managing Director of Berwind Private Equity. "We understand the AdaptDx™ has the potential to fundamentally transform the way eye doctors detect and manage AMD for millions of people worldwide."

"Closing our Series A round is a very significant achievement for the company," said John G. Edwards , CEO of MacuLogix. "We have completed numerous clinical studies involving more than 1,000 patients with additional studies ongoing, all at major research centers such as Harvard University, the National Eye Institute and University of Alabama at Birmingham. This financing allows us to take the next step."

About MacuLogix
MacuLogix is a pioneer in the early detection and tracking of age-related macular degeneration (AMD). MacuLogix' AdaptDx™ has received FDA 510(k) clearance for measurement of dark adaptation function and patient testing has been completed to support validation as a diagnostic for AMD. However, the AdaptDx™ is not currently cleared for sale as a diagnostic. In addition, the AdaptDx™ is being used by a number of pharmaceutical companies in the development of drugs for early AMD. 

For more information, visit www.maculogix.com


'/>"/>
SOURCE MacuLogix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Evergreen Healthcare Foundation Gala Raises Nearly $1.1 Million to Benefit Breast Health Center
2. Xtelligent Media Raises $800K in Funding and Launches EHRintelligence.com
3. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
4. BHI Raises Awareness of Hearing Aids as Potential Therapy to Help Quiet "Ringing in the Ears" During National Tinnitus Awareness Week
5. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
6. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
7. Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100
8. AssureRx Health Raises $12.5 Million Series C Financing
9. InnoPharma Inc. Raises $8 Million in Venture Debt
10. Lilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance
11. Retia Medical Raises $7 Million to Develop Accurate, Less-Invasive Cardiovascular Monitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... plc (NASDAQ: ENDP ) will announce its second-quarter 2017 ... management team will host a conference call and webcast before the ... The dial-in number to access the call is U.S./ Canada ... 45397076. Please dial in 10 minutes prior to the scheduled start ... the call will be available from August 8, 2017 at 11:30 ...
(Date:7/13/2017)... July 13, 2017  New York City-based market research firm ... should be aware of.  From new products to new costs, ... in a recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact ... aware of the impact the growing population and, to a ...
(Date:7/11/2017)... has awarded grants totaling more than $2 million to 16 ... Hemophilia Awards Program (BHAP). Four U.S. clinicians and researchers from ... Uniformed Services University of the Health Sciences in ... announced last night during a reception at the International Society ... Germany . ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The Karen ... services to communities in the greater Birmingham area, is joining the Chris Hammond ... young people in the region. , The Chris Hammond Youth Foundation maintains athletic ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... Fresh Wave® ... Liquid eco-friendly odor-control solution for colleges and universities at the APPA 2017 ... effectively eliminate severe cannabis and tobacco smoke odors without the use of harsh chemicals, ...
(Date:7/21/2017)... ... 2017 , ... Hospital M&A activity slowed in the second quarter of 2017, ... rose to 23 in the second quarter, up 15% from the 20 publicly announced ... deals in the year-ago second quarter. Only four of the transactions disclosed a purchase ...
(Date:7/21/2017)... ... 21, 2017 , ... The Margarian Law Firm has filed a class ... ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand of ... Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is made ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... received a $5,000 grant from the C. R. Bard Foundation, Inc. ... at Somerset Hills , a service available through the nonprofit home care agency. ...
Breaking Medicine News(10 mins):